Home › Funds › Aristotle Capital Boston, LLC › GRDN

Aristotle Capital Boston, LLC position in GRDN

GUARDIAN PHARMACY SVCS INC CL A · Consumer Staples

Aristotle Capital Boston, LLC reported holding 422,427 shares of GRDN (GUARDIAN PHARMACY SVCS INC CL A) in its Q2 2026 13F filing — a position valued at US$17.7M, representing 1.19% of its reported portfolio and ranking #36 among its reported holdings. Aristotle Capital Boston, LLC has disclosed GRDN holdings in 5 of the last 5 reported quarters, going back to Q2 2025.

Latest position (Q2 2026)422.43K sh
Reported value held$17.69M
Portfolio Weight1.19%
First reportedQ2 2025
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Aristotle Capital Boston, LLC's GRDN position evolved

Aristotle Capital Boston, LLC first disclosed a stake in GRDN in Q2 2025 at 409,673 shares (US$8.7M). The position peaked in Q1 2026 at 495,856 shares, worth US$18.7M. Across 5 filings, Aristotle Capital Boston, LLC increased the stake 1 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 422,427 shares valued at US$17.7M — a reduction of -73,429 shares quarter over quarter.. Notable position changes include a 59% increase in Q3 2025 (shares rose 15% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2025 409.67K $8.73M New
Q3 2025 649.46K $17.04M Add
Q4 2025 589.01K $17.72M Reduce
Q1 2026 495.86K $18.67M Reduce
Q2 2026 422.43K $17.69M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About GRDN and 13F data

GRDN (GUARDIAN PHARMACY SVCS INC CL A) is a Consumer Staples company. 71 other funds we track also report a position in GRDN — the largest reported positions include Valiant Capital Management, L.P. (US$49.7M), BOONE CAPITAL MANAGEMENT LLC (US$29.8M), Lisanti Capital Growth, LLC (US$6.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding GRDN

All GRDN fund holders →

FAQ

How long has Aristotle Capital Boston, LLC held GRDN?

Aristotle Capital Boston, LLC has disclosed GRDN holdings in 5 of the last 5 reported quarters, going back to Q2 2025.

What is Aristotle Capital Boston, LLC's current position in GRDN?

As of Q2 2026, Aristotle Capital Boston, LLC holds 422.43K shares of GRDN (GUARDIAN PHARMACY SVCS INC CL A), valued at $17.69M, representing 1.19% of its reported portfolio and ranking #36.

Has Aristotle Capital Boston, LLC been buying or selling GRDN?

In the latest 13F filing (Q2 2026), Aristotle Capital Boston, LLC reduced its position in GRDN. The position peaked in Q1 2026 at 495.86K shares.

Which other funds hold GRDN?

Other major institutional holders of GRDN include Valiant Capital Management, L.P., BOONE CAPITAL MANAGEMENT LLC, Lisanti Capital Growth, LLC, among 71 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.